Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

In the broader market, 78 stocks gained while 50 declined, with approximately 53 million shares worth S$86.3 million traded ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...

Swiss pharmaceutical giant Novartis raised its 2024 financial targets Tuesday after posting rising sales and margins in the third quarter, thanks in part to increased production of a prostate ...

Swiss pharmaceutical giant Novartis raised its 2024 financial targets Tuesday after posting rising sales and margins in the third quarter, thanks in part to increased production of a prostate cancer ...

Office workers walk out for a lunch break at Raffles Place central business district in Singapore on Oct 6, 2022. (File photo: AFP/Roslan RAHMAN) New: You can now listen to articles. SINGAPORE ...

C3G is a severe kidney disease that often leads to kidney failure within ten years of diagnosis. Credit: Orawan Pattarawimonchai/Shutterstock. Novartis has announced ...

Novartis on Monday became the latest Big Pharma player to jump into the molecular glue space. The Swiss drugmaker signed an exclusive development and commercialization agreement with Monte Rosa ...